Are the Current Recommendations for Chloroquine and Hydroxychloroquine Screening Appropriate?

Area of Science:

• Ophthalmology
• Rheumatology
• Pharmacology

Background:

• Hydroxychloroquine and quinacrine are common treatments for rheumatic diseases.
• Antimalarial therapies carry a risk of ocular toxicity, though infrequent.
• Existing recommendations for monitoring ocular toxicity are developed solely by ophthalmologists.

Purpose of the Study:

• To highlight the limitations of current ophthalmologist-developed recommendations for antimalarial ocular toxicity.
• To advocate for enhanced collaboration between ophthalmologists and rheumatologists in managing patients on these therapies.

Main Methods:

• Review of current literature and guidelines regarding antimalarial drug use in rheumatic diseases.
• Analysis of the data limitations and retrospective nature of existing recommendations.
• Discussion of the need for integrated patient management strategies.

Main Results:

• Current ocular toxicity recommendations are based on limited, retrospective data.
• Recommendations are developed without input from the rheumatologists who manage the primary rheumatic condition.
• A significant gap exists in the co-management approach for patients on antimalarial drugs.

Conclusions:

• Enhanced interaction between ophthalmologists and rheumatologists is crucial for comprehensive patient care.
• Future recommendations should incorporate multidisciplinary input to ensure patient safety and treatment efficacy.
• Improved co-management protocols are needed for rheumatic disease patients receiving antimalarial therapies.